AF
TCRR

Amalgamated Financial’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Amalgamated Financial’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$10K Buy
+3,672
New +$11.6K ﹤0.01% 2905

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Amalgamated Financial's TCRR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022: 3,672 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #2905 among its holdings.

94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Amalgamated Financial held 3,672 shares of TCR2 Therapeutics Inc. Common Stock worth $10K as of Q1 2022.
  • TCR2 Therapeutics Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • TCR2 Therapeutics Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2905 holding.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.